Trial to Extract Prognostic Factors Prior to the Start of Induction Chemotherapy for Adult AML

K. Kuriyama,M. Tomonaga,T. Kobayashi,K. Nishikawa,T. Ohsima,S. Furusawa,R. Ohno
DOI: https://doi.org/10.1007/978-3-642-71960-8_125
1998-01-01
Abstract:To predict prognoses of AML patients prior to the start of chemotherapy and to classify them according to their predicted prognoses, we analyzed the data on 545 (90%) patients out of 606 patients who were enrolled in the JALSG AML-87 or -89 protocol. Median age was 48 years. AML subtypes were as follow; AML-M1 was 96 (17.6%), M2 196 (36.0%), M3 107 (19.6%), M4 95 (17.4%), M5 31 (5.7%), M617 (3.1%) and M7 3 (0.6%). Eighty-nine patients(16%) were diagnosed as having trilineage dysplasia (TLD). We could elucidate seven good prognostic factors using multivariate analysis and gave them the weighted scores such as +2; ≤50 years of age, ≤ 20 000/mm3 of WBC, ≥ 50% of myeloperoxidase (MPO) positivity of blasts and presence of Auer bodies and +1; absence of TLD, FAB subtypes of AML-M2 or -M3 or -M4 with eosinophilia and ≤30 IU/l of serum glutamic oxaloacetic transaminase (GOT). A scoring system could classify the patients into three groups such as good (total scores; +9~+11) (149 cases, 53% at 5 years-survival), intermediate (+5~+8) (175 cases, 29%) and poor risk (0~+4) (95 cases, 10%). This system will be tested for feasibility in the next AML-92 protocol (about 700 cases) prospectively. If this procedure proves feasible, clinical trials could be designed based on such a risk group-stratification.
What problem does this paper attempt to address?